Cost-Effectiveness of Fulvestrant in Advanced Breast Cancer Treatment
Author Information
Author(s): Cameron D A, Camidge D R, Oyee J, Hirsch M
Primary Institution: Department of Oncology, Western General Hospital, Edinburgh, UK
Hypothesis
Is fulvestrant a cost-effective addition to the treatment sequence for ER-positive advanced breast cancer?
Conclusion
Fulvestrant is a cost-effective treatment option when added as a second- or third-line hormonal therapy for advanced breast cancer.
Supporting Evidence
- Fulvestrant as a second-line therapy provided an additional 47 life years and 41 quality-adjusted life years (QALYs) for 1000 patients.
- The cost per QALY gained with fulvestrant was estimated at £7300.
- Adding fulvestrant as a third-line option resulted in a cost reduction of £430 per patient.
Takeaway
This study shows that adding fulvestrant to breast cancer treatment can help patients live longer and better without costing too much money.
Methodology
A Markov model was developed to evaluate the cost-effectiveness of different treatment sequences for postmenopausal women with HR+ advanced breast cancer.
Potential Biases
Potential bias due to reliance on clinician surveys for treatment pathways and utility values.
Limitations
The analysis lacks direct clinical trial data comparing fulvestrant with other treatment sequences and relies on clinician estimates for utility values.
Participant Demographics
Cohort consisted of 1000 postmenopausal women with hormone-receptor positive advanced breast cancer.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website